|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Osteoporosis - Intermittent Dosing Drives Market Growth
Datamonitor, March 2007, Pages: 231
The long-standing unmet need of the osteoporosis market has been for improved adherence to treatment.
Two pipeline products, Amgens Denosumab and Novartis Aclasta (zoledronate), have answered this demand with intermittent dosing schedules and consequently are expected to generate blockbuster revenues.
This will rejuvenate the market which is otherwise stalling under multiple patent expiries.
Scope of this title:
Analysis of patient potential, unmet needs and clinical trial design in osteoporosis
Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the R&D pipeline
Detailed profiles of key compounds in development for use in osteoporosis, with forecasts of drug revenues to 2016
Review of the key strategies adopted by current market players
Highlights of this title:
Despite the genericization of the market leader Fosamax and patent expiries on other key brands, pipeline products are still viable. We expect pipeline products to swell the total market value 4.4% between 2007 and 2016 to $10.9 billion. Products that offer intermittent dosing schedules are highly desirable in the osteoporosis market and can generate blockbuster revenues. Such therapies answer the demand from patients and physicians for more convenient delivery mechanisms that increase compliance and ultimately improve treatment outcome. Although bisphosphonates are the mainstay of osteoporosis treatment, there is potential for new and innovative products to gain market share. Those that suit niche populations, such as Amgens ED-71 which finds favor as a vitamin D analogue in Japan, will be able to fight generic competition.
Reasons to order your copy:
Understand clinical and environmental unmet needs in the osteoporosis market based on key opinion leader comments
Benchmark key late-stage pipeline products against the current market leader and class comparator
Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential
Customers who bought this item also bought
Osteoporosis - Novel Agents to Battle for Payer Acceptance
Osteoporosis - The Science Of Compliance
Stakeholder Insight: Osteoporosis - Generic Alendronate Further Establishes Oral Bisphosphonates as Gold Standard
Osteoporosis Therapeutics - A Global Market Perspective
Osteoporosis Therapeutics - A Global Market Perspective
Drugs of Tomorrow: Osteoporosis - Will Bone Building Drugs Revolutionize the Market?
Pipeline Insight: Osteoporosis - Intermittent Dosing and Multiple Indications Drive Market Growth
Commercial Insight: Osteoporosis - Risk management and reformulation offer best defense against generic onslaught
Osteoporosis Therapeutics - Global Strategic Business Report
Chinese Markets for Osteoporosis Drugs
Commercial Insight: Osteoporosis and HRT - HRT is down for the count, but can osteoporosis players pick up the pieces?
Commercial Insight: Osteoporosis and HRT - Novel Osteoporosis Drugs Counter Generic Threat While HRT Players Regroup and Move Forward
|
|
|
|
